Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Small Cell Lung Cancer Limited Stage Clinical Trial

Official title:
A Phase II, Randomised Study of Toripalimab as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiotherapy

Status Recruiting

Clinical Trial Summary

The phase II, randomised study is to explore the efficacy and safety of toripalimab as consolidation therapy in patients with limited-stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lung Neoplasms
Small Cell Lung Cancer Limited Stage
Small Cell Lung Carcinoma

Clinical Trial Details

NCT number	NCT04418648
Study type	Interventional
Source	Sun Yat-sen University
Contact	Bo Qiu
Phone	+86-020-87343031
Email	qiubo@sysucc.org.cn
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2020
Completion date	May 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04882033` - Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer	Phase 1
Recruiting	`NCT04543890` - A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC	Phase 2
Completed	`NCT03059667` - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer	Phase 2
Completed	`NCT01797159` - Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer	N/A
Completed	`NCT03214003` - Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC	N/A
Recruiting	`NCT05651802` - PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients	N/A
Not yet recruiting	`NCT04189094` - Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC	Phase 2
Recruiting	`NCT05945745` - Molecular Analysis and Treatment Options of SCLC
Recruiting	`NCT04602533` - Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)	Phase 2